SUNNYVALE, Calif., July 22, 2020 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today the appointment of
Anne B. Le Grand to the company's
Board of Directors, effective as of July 16,
2020. In addition, she will serve on the Board's Nominating
and Corporate Governance Committee. With Ms. Le Grand's appointment, the Accuray Board will
consist of nine members.
Ms. Le Grand is an experienced
healthcare executive with over 25 years of experience in the global
healthcare technology industry. She brings invaluable expertise
leading the development and commercialization of medical imaging
technology, one of the most important areas of focus in the
radiation oncology arena. Since 2016, Ms. Le Grand has served as Vice President IBM and
General Manager Watson Health Imaging. Prior to joining IBM, Ms.
Le Grand held multiple senior
level leadership positions at Philips Health Systems, including
most recently, Senior Vice President Healthcare and General
Manager, Therapeutic Care. Previous to her tenure at Philips, Ms.
Le Grand served as Senior Vice
President Healthcare and General Manager Global X-ray for General
Electric Healthcare, where she successfully launched refreshed
portfolios across General Electric Healthcare's global x-ray,
mammography and lunar businesses.
"Anne's appointment to the Board reinforces Accuray's commitment
to driving innovation of our product portfolio that meets the needs
of an evolving radiation therapy market. She has a proven track
record in the medical device industry for introducing market-driven
products that are the foundation for consistent financial growth.
Anne's marketing acumen and global commercialization expertise will
be invaluable during this important period in Accuray's business,"
said Joshua H. Levine, President and
Chief Executive Officer.
"I'm delighted to have the opportunity to join Accuray's Board
of Directors and be a part of a company dedicated to improving the
lives of people diagnosed with cancer, benign tumors, or neurologic
disorders. I believe my experience can help the company take its
industry-leading radiation therapy products to a new level,
facilitating the achievement of long-term growth and profitability
goals while making it easier for customers to attain their clinical
and ROI objectives," said Anne Le
Grand.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter
and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expectations regarding the
company's products, growth and profitability. These forward-looking
statements involve risks and uncertainties. If any of these risks
or uncertainties materialize, or if any of the company's
assumptions prove incorrect, actual results could differ materially
from the results expressed or implied by these forward-looking
statements.
These risks and uncertainties include, but are not limited to,
risks related to the effect of the COVID-19 pandemic, or the
perception of its effects, on the company's operations and the
operations of its customers and suppliers; the company's ability to
achieve widespread market acceptance of its products, including new
product offerings; the company's ability to effectively integrate
and execute its China joint
venture strategy; risks and uncertainties related to future Type A
and B license announcements in China; risks inherent in
international operations; and such other risks identified under the
heading "Risk Factors" in the company's Quarterly Report on Form
10-Q, filed with the Securities and Exchange
Commission (the "SEC") on May 8, 2020 and as updated
periodically with the company's other filings with
the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Investor Contact:
Joe Diaz
Investor Relations, Lytham Partners
+1 (602) 889-9700
diaz@lythampartners.com
Media Contact:
Beth
Kaplan
Accuray
+1 (408)
789-4426
bkaplan@accuray.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anne-b-le-grand-joins-accuray-board-of-directors-301098249.html
SOURCE Accuray Incorporated